[Prolonged curarization in the newborn infant under assisted ventilation for idiopathic respiratory distress].
We studied the effects of prolonged pancuronium administration in 10 neonates under assisted ventilation for hyaline membrane disease. Pancuronium bromide was administered from the time of intubation with a load dose of 0.1 mg/kg followed by a continuous infusion of 0.03-0.07 mg/kg/h. Tolerance, especially cardiovascular, was excellent after 72 to 525 h of therapy (mean 173 h). Oxygen needs, incidence of mechanical complications and the general evolution of idiopathic respiratory distress were not significantly affected by muscle relaxation. The benefits of systematic pancuronium administration during respiratory intensive care in neonates with hyaline membrane disease appear to be of little value when considering the necessary constraints (corneal, cutaneous, vesical and tracheal supervision).
D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010197:Pancuronium / Q000008:administration & dosage; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*; D013997:Time Factors
D003473:Neuromuscular Nondepolarizing Agents; D010197:Pancuronium
La curarisation prolongée chez le nouveau-né en ventilation assistée pour détresse respiratoire idiopathique.